Trial
NCT01892345
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Neuromyelitis Optica
Intervention
Eculizumab
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-26